Telix is a "theranostics" company developing a pipeline of late-stage oncology assets in prostate cancer, renal cancer and glioblastoma. Telix Pharmaceuticals, TLX (ASX) is a clinical-stage company focusses on development of radiopharmaceuticals for localisation and treatment of cancer. Telix has a pipeline of imaging and therapeutic radiopharmaceuticals for renal, prostrate and brain cancer.
Telix Pharmaceuticals Limited
[stock_market_widget type=”leaderboard” template=”color-frame” color=”yellow” assets=”TLX.AX” api=”yf” style=”font-size: 15px”]
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/telixpharma” connections=”true” suffix=””]
Telix Pharmaceutical uses Molecularly-targeted radiation (MTR) therapies to image and treat cancer. In MTR therapy, a radionuclide is attached to a targeting agent such as a small molecule or antibody. This targeting agent specifically binds to tumours and delivers a radioactive payload in a highly selective way; killing cancer cells, shrinking tumours and halting their growth. MTR therapies are very selective and are typically well tolerated by patients.
In Apr 2018, Telix Pharmaceuticals Limited announced a research partnership with the French National Institute of Health and Medical Research and the _Accelerator for Research in Radiochemistry and Oncology at Nantes AtlanticÓ (ARRONAX). Under the research partnership, Telix will explore the feasibility of using several of its clinical targeting agents with astatine. Astatine is an _alpha emitterÓ, a very high-energy radionuclide that is capable of significantly altering the tumour microenvironment when attached to a molecular targeting agent that is specific for cancer cells.